International Journal For Multidisciplinary Research

E-ISSN: 2582-2160   •   Impact Factor: 9.24

A Widely Indexed Open Access Peer Reviewed Multidisciplinary Bi-monthly Scholarly International Journal

Call for Paper Volume 7, Issue 4 (July-August 2025) Submit your research before last 3 days of August to publish your research paper in the issue of July-August.
Submit Research Paper Join as a Reviewer

Plagiarism is checked by the leading plagiarism checker TurnItIn

Call for Paper

Volume 7 Issue 4
July-August 2025

Submit your research paper

Indexing Partners
Academia Advanced Sciences Index Bielefeld Academic Search Engine CiteSeer DRJI Google Scholar Independent Search Engine & Directory Network ISI (International Scientific Indexing) Issuu Mendeley Research Networks
RefSeek ResearcherId - Thomson Reuters ResearchGate Scirus Scribd Semantic Scholar UTeM - Universiti Teknikal Malaysia Melaka Wiki for Call for Papers WorldCat Zenodo

Comparative Effectiveness of SGLT2 Inhibitors Versus GLP-1 Receptor Agonists in Reducing Cardiovascular Events in Type 2 Diabetes

Author(s) Dr. Olaniran Samuel Olabode, Dr. Adebori John Agunbiade, Dr. Jay S Bhatt, Dr. Emad Asasfeh, Dr. Aruna Misir
Country India
Abstract Type 2 diabetes mellitus (T2DM) is a global health burden affecting over 500 million people, with cardiovascular disease (CVD) being the predominant cause of death among these patients. Traditionally, antidiabetic therapies focused solely on glycemic control, but recent evidence emphasizes the importance of cardiovascular risk reduction. Sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are two novel classes of antidiabetic agents that have shown cardiovascular benefits beyond glucose lowering in large cardiovascular outcome trials. Despite widespread use, their comparative effectiveness in preventing major cardiovascular events remains uncertain, warranting a direct evaluation to guide personalized therapy.
To systematically compare the cardiovascular outcomes of SGLT2 inhibitors versus GLP-1 receptor agonists in patients with T2DM, focusing on major adverse cardiovascular events (MACE), cardiovascular mortality, heart failure hospitalization, and all-cause mortality.
A systematic search was conducted across PubMed, EMBASE, Cochrane Library, and Scopus databases for studies published up to June 2025. Eligible studies included randomized controlled trials (RCTs) and high-quality observational cohorts that reported direct or indirect comparisons of SGLT2 inhibitors and GLP-1 RAs in adults with T2DM. Study selection and data extraction were performed independently by two reviewers. The primary outcomes were MACE (composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke) and cardiovascular mortality. Secondary outcomes included hospitalization for heart failure (HHF) and all-cause mortality. Risk of bias was assessed using the Cochrane RoB 2 and ROBINS-I tools.
Results:
A total of 21 studies (12 RCTs and 9 observational studies) comprising over 180,000 patients were included. Both drug classes significantly reduced MACE compared to placebo. SGLT2 inhibitors demonstrated superior reduction in heart failure hospitalization (HR: 0.75; 95% CI: 0.68–0.84) and showed favorable outcomes in patients with pre-existing heart failure or chronic kidney disease. GLP-1 receptor agonists showed a slightly greater effect in reducing nonfatal stroke (HR: 0.87; 95% CI: 0.78–0.96) and had comparable effects on cardiovascular and all-cause mortality to SGLT2 inhibitors.
Conclusions:
SGLT2 inhibitors and GLP-1 receptor agonists both significantly reduce cardiovascular risk in patients with T2DM, though with differing strengths. SGLT2 inhibitors appear more effective in preventing heart failure-related outcomes, while GLP-1 receptor agonists offer marginally better protection against cerebrovascular events. These findings support a patient-centered approach in choosing glucose-lowering therapies based on individual cardiovascular profiles.
Keywords SGLT2 inhibitors, GLP-1 receptor agonists, type 2 diabetes, cardiovascular disease, MACE, heart failure, systematic review
Field Biology
Published In Volume 7, Issue 4, July-August 2025
Published On 2025-07-18
DOI https://doi.org/10.36948/ijfmr.2025.v07i04.51435
Short DOI https://doi.org/g9tz74
View / Download PDF File

Share this



E-ISSN 2582-2160
CrossRef

CrossRef DOI is assigned to each research paper published in our journal.

IJFMR DOI prefix is
10.36948/ijfmr

Downloads
Research Paper Format Copyright Permission Form and Undertaking Form Cover Page Vol 7 Isu 4Cover Page Vol 7 Isu 3Cover Page Vol 7 Isu 2

All research papers published on this website are licensed under Creative Commons Attribution-ShareAlike 4.0 International License, and all rights belong to their respective authors/researchers.

CC-BY-SA Open Access

About IJFMR
Fees & Payment
Current Issue
Publication Archive 		Submit Research Paper
Track Submission Status
Publication Guidelines
Publication Ethics
Peer Review & Plagiarism 		Join as a Reviewer
Editors & Reviewers
Reviewer Referral Program
Get Reviewer Membership Certi. 		Website/Journal Policies
Usage Policy
Content Policies
Privacy Policy
Contact Us +91-9687-828-838 editor@ijfmr.com